Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Optimizing methods of clinical sample processing for scRNA-seq and mechanistic studies in sepsis to enable reliable, reproducible, and high-yield multi-center collection efforts

Award Number: R33GM148826
ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2023
PERIOD OF PERFORMANCE END DATE: 12/31/2026

Group Awards By:

View Award Description

Optimizing methods of clinical sample processing for scRNA-seq and mechanistic studies in sepsis to enable reliable, reproducible, and high-yield multi-center collection efforts - Project summary: Sepsis is prevalent, costly, and deadly. In the U.S, sepsis accounts for 4% of hospitalizations, 13% of in-hospital healthcare expenditures, and 35% of in-hospital deaths. Although common, sepsis is often difficult to diagnose and treat effectively, since it is a syndrome defined generically by organ dysfunction resulting from a dysregulated immune response to infection. This broad definition leads to heterogeneity of disease and misdiagnosis. Clinical trials thus enroll ill-characterized populations of sepsis patients with variable underlying immune responses to infection, diluting the effects of novel and otherwise promising therapies that might benefit a defined subset of patients. Precision immune cell-specific characterization of the dysregulated host immune response in sepsis is clearly needed. Our group was the first to elucidate an immunosuppressive monocyte substate (MS1) expanded in patients with urosepsis (Reyes et al. Nat Med 2020) using single cell RNA sequencing (scRNA-seq), which resolves cellular heterogeneity, revealing rich signatures of immune cell-specific gene expression not evident from standard immune profiling techniques. Clinical investigation in sepsis would greatly benefit from the scalable deployment of scRNA-seq across multicenter studies and clinical trials to enable robust characterization of the host immune response in sepsis, and to explain the effect of disease heterogeneity on clinical course, outcomes, and treatment effects. Yet in order to facilitate subsequent scRNA-seq, immune cells must be isolated from whole blood samples, which currently involves complex real-time processing of fresh blood at clinical sites, a process neither practical nor reproducible enough to allow deployment across multiple clinical centers. To address this critical need, we piloted a simple method of onsite whole blood cryopreservation that uses only 2 mL of blood and is easily deployable at clinical sites, followed by storage for scRNA-seq at a centralized center of expertise. In the R21 phase, we will optimize and validate our method of whole blood cryopreservation on enrolled subjects at 2 local clinical sites versus gold standard methods for immune cell isolation. We will compare scRNA-seq technical quality metrics and biologically-relevant measures including the MS1 monocyte subtype and other immune cell states. Importantly, we will test the viability and function of cryopreserved cells in mechanistic studies. In the R33 phase, we will scale our whole blood cryopreservation method to 5 enrolling clinical sites around the U.S. to demonstrate feasibility of a multicenter collection with centralized scRNA-seq and analysis. In this expanded sepsis cohort, we will perform deep immune profiling and derive scRNA-seq- based endotypes to characterize underlying heterogeneity of host immune responses. We will compare these endotypes to those derived from bulk RNA sequencing and apply scRNA-seq-derived signatures to our own clinical trials data that have obtained bulk RNA sequencing. The proposed studies are highly likely to make available a simple method to facilitate single-cell immune profiling in multicenter studies to greatly enhance our understanding of the host immune response in sepsis and guide the development of targeted therapies.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $647,898 )
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Biomedical Research and Research Training	000	4	12/22/2025	NON-COMPETING CONTINUATION	$583,109
2026	2026	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Biomedical Research and Research Training	001	4	3/10/2026	NON-COMPETING CONTINUATION	$64,789
														Subtotal = $647,898

Issue Date FY: 2025 ( Subtotal = $676,179 )
2025	2025	THE GENERAL HOSPITAL CORPORATION	55 FRUIT ST	BOSTON	MA	02114	SUFFOLK	USA	Biomedical Research and Research Training	000	3	12/5/2024	EXTENSION WITH OR WITHOUT FUNDS	$676,179
														Subtotal = $676,179

Grand Total All Awards = $1,324,077

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Optimizing methods of clinical sample processing for scRNA-seq and mechanistic studies in sepsis to enable reliable, reproducible, and high-yield multi-center collection efforts

Award Number: R33GM148826

ORGANIZATION: NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2023

PERIOD OF PERFORMANCE END DATE: 12/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer